Harvard Bioscience, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Bruce Jackson from Benchmark Co. maintained a Buy rating on the stock and has a $3.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Bruce Jackson’s rating is based on Harvard Bioscience’s recent announcement of surpassing revenue expectations for the second quarter, reporting approximately $20.4 million compared to the anticipated $18.8 million. This positive financial performance indicates strong operational execution and potential for continued growth.
Additionally, the company’s leadership transition, with John Duke stepping in as the new President and CEO, along with the appointment of two new independent directors, Rob Gagnon and Seth Benson, suggests a strategic direction that could further enhance shareholder value. These factors collectively contribute to the Buy rating, reflecting confidence in the company’s future prospects.